phase II clinical study
Calithera Biosciences Begins Phase II Trial of Mivavotinib in DLBCL
The company will evaluate the drug in a subset of DLBCL patients with non-germinal center B-cell like disease including those with MYD88 or CD79b mutations.
MD Anderson, Turning Point Therapeutics Partner to Study Repotrectinib, Elzovantinib
The research will include preclinical and clinical studies of ROS1/NTRK inhibitor repotrectinib and MET inhibitor elzovantinib in several tumor types.
Bolstered by the success of KRAS G12C inhibitors in lung cancer, smaller firms are developing drugs for a range of other KRAS-mutated cancers and trying to anticipate resistance.Â
Acrivon Therapeutics to Study CHK1/2 Inhibitor ACR-368, Predictive Diagnostic in Phase II Trial
The trial will enroll patients with ovarian, endometrial, and urothelial cancer, and stratify them for treatment using Acrivon's OncoSignature proteomic diagnostic.
Recursion Launches Clinical Trial for Targeted Drug in NF2-Mutated Meningioma Patients
The trial will pit Recursion's HDAC inhibitor REC-2282 against a placebo in patients with progressive meningiomas harboring NF2 mutations.